Tumor Treating Fields (TTFields) is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. [Science of TTFields]. TTFields are delivered to the body region where the tumor is located using an investigational medical device, called Optune® with High Intensity Transducer Arrays. The device is a portable, light-weight, battery operated device designed to deliver TTFields to the brain.
Patients receiving TTFields need to wear four arrays on their scalp, which deliver the fields non-invasively to the brain and are replaced on a regular basis. [Living with TTFields]. The device is intended for continuous home use by patients.
Optune® has been approved for the treatment of recurrent and newly diagnosed GBM by the Food and Drug Administration (FDA) in the United States under the Premarket Authorization (PMA) pathway and has obtained a CE mark in Europe for the same indications. In addition TTFields have been recently approved as Optune Lua (formerly NovoTTF-100L) for malignant pleural mesothelioma by the FDA, in combination with chemotherapy, under the Humanitarian Device Exemption pathway.